Mst Continus (Morphine Sulfate)

Morphine sulfate binds to mu‑opioid receptors in the brain and spinal cord, activating inhibitory pathways that reduce the transmission of pain signals. This receptor activation leads to decreased neuronal excitability and a higher pain threshold, providing effective analgesia.

The appropriate dose of Mst Continus is individualized and determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. Dosage adjustments are made to achieve adequate pain control while minimizing adverse effects.

Safety data for morphine sulfate during pregnancy and lactation are limited. It is generally contraindicated in pregnant women unless the potential benefit outweighs the risk to the fetus. Morphine can pass into breast milk, so breastfeeding is usually discouraged while using this medication.

To order Mst Continus, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Morphine sulfate is considered a benchmark opioid with well‑characterized efficacy and safety. Compared with alternatives such as oxycodone or hydromorphone, morphine has a longer history of use and a predictable conversion ratio, but individual response and side‑effect profiles may vary, making clinician judgment essential.

Mst Continus should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure it is out of reach of children and unauthorized personnel.

Mst Continus is intended for oral administration. The tablet (or oral formulation) should be swallowed whole with a full glass of water. It should not be crushed, chewed, or dissolved unless specifically directed by a healthcare professional.

The most serious risks include respiratory depression, which can be life‑threatening, especially in opioid‑naïve patients or when combined with other depressants. Additional concerns are severe hypotension, profound sedation, dependence, and the potential for overdose.

Mst Continus is contraindicated in patients with significant respiratory depression, acute or severe asthma, paralytic ileus, known hypersensitivity to morphine or other opioids, and in individuals taking monoamine oxidase inhibitors within 14 days. Clinicians should evaluate each patient’s medical history before prescribing.